InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.90
(
-0.02%
)
Bitcoin
56,998.63
(
-5.26%
)
Post# of 252482
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: DewDiligence post# 212581

Monday, 07/24/2017 8:18:12 PM

Monday, July 24, 2017 8:18:12 PM

Post# of 252482
RETA:

I think this type of situation is always a possibility.

The drug's impact on eGFR was not in doubt, and was published in the NEJM paper. The issue is how you finesse a drug that increases mortality in the long term versus this short term trial outcome.

This is a prime example of a "catalyst" field of view versus a long term fundamental view.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up